Stocks head into the final day of July with the best monthly gain in a year, yet July's hot performance has only sparked debate about what August will bring.
The biotechnology bellwether reported an improved adjusted profit of $1.38 a share. Sales rose 2 percent to $3.8 billion, against $3.71 billion a year earlier.
What follows is a roundup of corporate earnings reports for Thursday, July 29.
Weekly jobless claims will again be a big event for Thursday's markets, and economists think the number will not really show any improvement.
Stocks surged Thursday with the Dow jumping at least 200 points after another strong batch of earnings reports. Sandy Lincoln, investment strategist at M&I Investment Management, and Bill Smead, CEO and CIO of Smead Capital Management, shared their insights.
Here's what analysts and others say they're watching before the bell Thursday.
Companies have been hoarding more cash more than ever due to concerns over a double-dip recession and uncertainties in the environment.
Following a poor quarterly performance for most of the major averages, investors seeking opportunities for the rest of the year may want to look at companies with the potential to weather any potential "double dips". One of the metrics that is closely watched by Wall Street is the amount of cash available.
Stocks tumbled Friday, with the Dow falling more than 2 percent. Which stocks should you be buying and selling into next week? Danielle Hughes, founder and CEO of Divine Capital, and Charlie Smith, CIO of Fort Pitt Capital Group, discussed their best plays.
Following are moves you might have missed. Find out why shares of Shanda Games and Amgen popped while Best Buy and Blue Nile dropped.
Stocks logged their third best day of the year Wednesday, led by energy and financials, as investors grabbed bargain shares beaten down in the prior session's selloff. A report showing pending-home sales hit a six-month high gave the market an extra boost.
Stocks remained higher Wednesday, led by energy and financials, as investors grabbed bargain shares beaten down in the prior session's selloff. A report showing pending-home sales hit a six-month high gave the market an extra boost.
What follows is a look at stocks in the S&P 500 displaying unusual volume in today's trading session.
Fears of global economic contagion sent the markets falling for the second day in a row, pushing the Dow below 10,000. But Bill Smead, CEO and CIO of Smead Capital Management and Craig Hodges, co-portfolio manager at The Hodges Fund said they still remain bullish on the markets.
The euro fell broadly on Monday, after the Spanish central bank's takeover of a savings bank added to jitters about debt problems in some of the weak euro zone countries. Where should investors be putting their money? Jason Trennert, chief investment strategist and managing partner at Strategas Research Partners, shared his views and investment strategies.
As the Amgen Tour of California—the largest cycling event in the U.S.—was hitting its stride, the Wall Street Journal broke the story that former Tour de France champion Floyd Landis admitted to doping. He also implicated others, including some riding in this week's Tour, like Lance Armstrong. Armstrong again denies the allegations.
Drug developer Celgene is expected to release data on from two studies in coming weeks, and the bulls are looking for a rally.
The Dow clawed back in late trading Wednesday. Technology and industrials gained while health-care and telecom shares continued to drag.
Amgen says better sales of its anti-infection drugs helped lift first-quarter profit 15 percent, but cautions that health care reform measures will tamp down full-year results.
What follows is a roundup of corporate earnings reports for Wednesday, April 21.